Korro Bio (NASDAQ:KRRO) Price Target Raised to $90.00 at Royal Bank of Canada

Korro Bio (NASDAQ:KRRO) had its price target boosted by Royal Bank of Canada from $70.00 to $90.00 in a report released on Wednesday, Benzinga reports. The firm currently has an outperform rating on the stock.

Other research analysts have also issued reports about the stock. HC Wainwright reiterated a buy rating and issued a $100.00 target price on shares of Korro Bio in a research report on Friday, January 19th. BMO Capital Markets reaffirmed an outperform rating and set a $120.00 price target on shares of Korro Bio in a research note on Tuesday.

Korro Bio Trading Up 1.8 %

KRRO stock opened at $88.53 on Wednesday. The business has a 50 day moving average of $54.43. The stock has a market cap of $65.51 million, a PE ratio of -0.94 and a beta of 2.09. Korro Bio has a one year low of $9.15 and a one year high of $97.91.

Institutional Trading of Korro Bio

Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. bought a new position in shares of Korro Bio during the fourth quarter valued at about $12,988,000. Eventide Asset Management LLC bought a new position in Korro Bio during the 4th quarter worth approximately $26,185,000. 72 Investment Holdings LLC purchased a new position in Korro Bio in the 4th quarter worth approximately $13,269,000. Point72 Asset Management L.P. bought a new stake in Korro Bio in the fourth quarter valued at approximately $12,741,000. Finally, Verition Fund Management LLC purchased a new stake in shares of Korro Bio during the fourth quarter valued at approximately $2,784,000. 13.18% of the stock is owned by institutional investors.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc is based in Cambridge, Massachusetts.